BACKGROUND: In recent years, human and animal studies have converged to support altered inflammatory signaling as a molecular mechanism underlying the pathophysiology of alcohol use disorders (AUDs). Alcohol binds to receptors on immune cells, triggering signaling pathways that produce pro-inflammatory cytokines. Chronic inflammation is associated with tissue damage, which may contribute to negative effects of AUD. Conversely, cannabis is associated with decreased inflammatory signaling, and animal studies suggest that cannabinoids may impact alcohol-induced inflammation. Thus, the impact of cannabis on inflammation in AUDs in humans warrants examination. METHODS: We explored the relationship between self-reported alcohol and cannabis use and circulating levels of the pro-inflammatory cytokines interleukin 6 (IL-6), IL-8, and IL-1β in the blood. Among 66 regular drinkers (mean age = 30.08), we examined circulating cytokines and administered questionnaires assessing alcohol consumption and days of cannabis use over the past 90 days. We examined whether alcohol consumption, cannabis use, and gender were associated with changes in circulating cytokines, and whether there was a significant interaction between alcohol and cannabis use predicting blood levels of circulating cytokines. RESULTS: A positive association between alcohol and IL-6 emerged. We also observed a negative association between cannabis and IL-1β. Follow-up moderation analyses indicated a cannabis by alcohol interaction predicting circulating IL-6, such that cannabis nonusers showed a stronger relationship between alcohol and IL-6 compared to cannabis users. CONCLUSIONS: These preliminary findings suggest that cannabinoid compounds may serve to mitigate inflammation associated with alcohol use. In addition, the present results provide data to inform future investigations, with the goal of ultimately leveraging knowledge of the role of inflammation in AUDs to develop more effective treatments focused on novel immune targets.
BACKGROUND: In recent years, human and animal studies have converged to support altered inflammatory signaling as a molecular mechanism underlying the pathophysiology of alcohol use disorders (AUDs). Alcohol binds to receptors on immune cells, triggering signaling pathways that produce pro-inflammatory cytokines. Chronic inflammation is associated with tissue damage, which may contribute to negative effects of AUD. Conversely, cannabis is associated with decreased inflammatory signaling, and animal studies suggest that cannabinoids may impact alcohol-induced inflammation. Thus, the impact of cannabis on inflammation in AUDs in humans warrants examination. METHODS: We explored the relationship between self-reported alcohol and cannabis use and circulating levels of the pro-inflammatory cytokines interleukin 6 (IL-6), IL-8, and IL-1β in the blood. Among 66 regular drinkers (mean age = 30.08), we examined circulating cytokines and administered questionnaires assessing alcohol consumption and days of cannabis use over the past 90 days. We examined whether alcohol consumption, cannabis use, and gender were associated with changes in circulating cytokines, and whether there was a significant interaction between alcohol and cannabis use predicting blood levels of circulating cytokines. RESULTS: A positive association between alcohol and IL-6 emerged. We also observed a negative association between cannabis and IL-1β. Follow-up moderation analyses indicated a cannabis by alcohol interaction predicting circulating IL-6, such that cannabis nonusers showed a stronger relationship between alcohol and IL-6 compared to cannabis users. CONCLUSIONS: These preliminary findings suggest that cannabinoid compounds may serve to mitigate inflammation associated with alcohol use. In addition, the present results provide data to inform future investigations, with the goal of ultimately leveraging knowledge of the role of inflammation in AUDs to develop more effective treatments focused on novel immune targets.
Authors: Sophie Leclercq; Sébastien Matamoros; Patrice D Cani; Audrey M Neyrinck; François Jamar; Peter Stärkel; Karen Windey; Valentina Tremaroli; Fredrik Bäckhed; Kristin Verbeke; Philippe de Timary; Nathalie M Delzenne Journal: Proc Natl Acad Sci U S A Date: 2014-10-06 Impact factor: 11.205
Authors: Sophie Leclercq; Christine De Saeger; Nathalie Delzenne; Philippe de Timary; Peter Stärkel Journal: Biol Psychiatry Date: 2014-02-14 Impact factor: 13.382
Authors: He Benny Chang; Sara Munroe; Katarina Gray; Giovanna Porta; Antoine Douaihy; Anna Marsland; David Brent; Nadine M Melhem Journal: J Affect Disord Date: 2018-09-07 Impact factor: 4.839
Authors: Lemmy Schakel; Dieuwke S Veldhuijzen; Henriët van Middendorp; Corine Prins; Anne M H F Drittij; Frank Vrieling; Leo G Visser; Tom H M Ottenhoff; Simone A Joosten; Andrea W M Evers Journal: J Med Internet Res Date: 2020-07-24 Impact factor: 5.428
Authors: Ana Maria Baptista Menezes; Paula Duarte Oliveira; Fernando César Wehrmeister; Maria Cecilia F Assunção; Isabel O Oliveira; Luciana Tovo-Rodrigues; Gustavo Dias Ferreira; Helen Gonçalves Journal: PLoS One Date: 2019-05-09 Impact factor: 3.240
Authors: Heikki Laurikainen; Arja Vuorela; Anna Toivonen; Linnea Reinert-Hartwall; Kalevi Trontti; Maija Lindgren; Jaakko Keinänen; Teemu Mäntylä; Janina Paju; Tuula Ilonen; Reetta-Liina Armio; Maija Walta; Jouni Tuisku; Semi Helin; Päivi Marjamäki; Iiris Hovatta; Sebastian Therman; Outi Vaarala; Outi Linnaranta; Tuula Kieseppä; Raimo K R Salokangas; Jarno Honkanen; Jarmo Hietala; Jaana Suvisaari Journal: Transl Psychiatry Date: 2020-03-16 Impact factor: 6.222